Verucerfont

Verucerfont

Systematic (IUPAC) name
3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(1S)-1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]pyrazolo[1,5-a]pyrimidin-7-amine
Clinical data
Routes of administration	Oral
Identifiers
CAS Number	885220-61-1
ATC code	none
PubChem	CID: 11596613
ChemSpider	28295024
UNII	X60608B091 Y
Chemical data
Formula	C22H26N6O2
Molecular mass	406.480 g/mol
SMILES CC[C@@H](c1nc(no1)C)Nc2cc(nc3n2nc(c3c4cccc(c4C)OC)C)C
InChI InChI=1S/C22H26N6O2/c1-7-17(22-24-15(5)27-30-22)25-19-11-12(2)23-21-20(14(4)26-28(19)21)16-9-8-10-18(29-6)13(16)3/h8-11,17,25H,7H2,1-6H3/t17-/m0/s1 Key:NZQAFTPOKINLRY-KRWDZBQOSA-N

Verucerfont (GSK-561,679) is a drug developed by GlaxoSmithKline which acts as a CRF-1 antagonist. Corticotropin releasing factor (CRF), also known as Corticotropin releasing hormone, is an endogenous peptide hormone which is released in response to various triggers such as chronic stress, and activates the two corticotropin-releasing hormone receptors CRH-1 and CRH-2. This then triggers the release of corticotropin (ACTH), another hormone which is involved in the physiological response to stress.

Verucerfont blocks the CRH-1 receptor, and so reduces ACTH release following chronic stress. It is under investigation as a potential treatment for alcoholism, as chronic stress is often a factor in both development of alcoholism and relapse in recovering alcoholics. It has shown promising results in animal studies but has not been tested in humans.

See also

• Antalarmin
• Corticotropin releasing hormone antagonists
• Pexacerfont